Krystal Biotech (KRYS) Capital Expenditures (2016 - 2026)

Krystal Biotech has disclosed Capital Expenditures across 11 years of filings, most recently posting $7.1 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $7.1 million, up 411.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.8 million (up 412.58% YoY), and the FY2025 annual result was $3.1 million, down 27.63% from the prior year.
• Capital Expenditures came in at $7.1 million for Q1 2026 at Krystal Biotech, up from $2.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $19.2 million in Q2 2022 to a low of -$18.4 million in Q3 2022.
• The 5-year median for Capital Expenditures is $1.0 million (2024), against an average of $2.2 million.
• Across the five-year window, Capital Expenditures soared 896.19% in 2024 and sank 815.58% in 2025, its largest moves.
• Krystal Biotech's Capital Expenditures stood at -$378000.0 in 2022, then slumped by 561.64% to -$2.5 million in 2023, then jumped by 132.03% to $801000.0 in 2024, then jumped by 205.12% to $2.4 million in 2025, then soared by 192.47% to $7.1 million in 2026.
• The last three Capital Expenditures figures came in at $7.1 million (Q1 2026), $2.4 million (Q4 2025), and -$7.5 million (Q3 2025), per Business Quant data.